Vivacelle Bio
Vivacelle Bio is a late-stage biopharmaceutical company focused on developing life-saving, nanoparticle-based therapies for septic shock and severe blood loss. Their innovative platform utilizes phospholipid nanoparticles to restore intravascular volume and redistribute nitric oxide, addressing both relative and absolute hypovolemia, which are critical in treating septic shock and hemorrhagic conditions.
Vivacelle Bio
What We Do
Clinical Trials
Vivacelle Bio is conducting Phase 3 trials for its lead asset, VBI-S, aimed at treating patients with hypovolemia due to septic shock. The trial is designed to compare VBI-S with standard care to assess its efficacy in increasing mean arterial blood pressure.
Innovative Therapies
The company develops nanoparticle-based therapies that target the underlying causes of septic shock and severe blood loss, providing a new paradigm in fluid resuscitation.
A phospholipid nanoparticle-based cardiovascular support fluid currently in Phase III trials, designed to treat hypotension and hypovolemia in septic shock patients. It has met all endpoints in Phase II trials.
VBI-1
A refined version of VBI-S, ready to start Phase II trials, showing early evidence to treat hemorrhagic shock and reperfusion injury.
Application Area
Drugs
Routes of Administration
Funded Projects
Open Clinical Trial for the Evaluation of Novel Phospholipid Nanoparticles for the Treatment of Septic Shock
Vivacelle Bio was cleared by the FDA to proceed with its Phase IIa clinical trial for evaluation of the safety and efficacy of VBI-S, an intravenously injected cardiovascular support fluid containing micelles and liposomes to treat septic shock. The beneficial action of VBI-S occurs through its ability to redistribute nitric oxide, a gas that is overproduced in septic shock and causes potentially fatal low blood pressure and organ damage.
News & Updates
Recognizing the leading cause of death in U.S. hospitals, Vivacelle Bio highlights the importance of awareness and treatment for sepsis.
The company has initiated its Phase 3 trial for VBI-S, enrolling patients with hypovolemia due to septic shock.
A multicentre, open-label, repeated measures, phase 2 study published in The Lancet, detailing the efficacy and safety of VBI-S.